Wolfgang Jahnke

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Jianming Zhang, Francisco Adrián, Wolfgang Jahnke et al. · Nature · 2010 · 590 citations

Molecular Pharmacology, Drug Target, Medicine +5

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 574 citations

Molecular Pharmacology, Drug Target, Medicine +3

A simple protocol for amino acid type selective isotope labeling in insect cells with improved yields and high reproducibility

Alvar D. Gossert, Alexandra Hinniger, Sascha Gutmann et al. · Journal of Biomolecular NMR · 2011 · 473 citations

Biology, Biosynthesis, Biochemistry +10

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini et al. · Journal of Medicinal Chemistry · 2018 · 432 citations · Full text

Drug Target, Mixed-phenotype Acute Leukemia, Molecular Biology +16

The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation

Sandra W. Cowan‐Jacob, Gabriele Fendrich, Paul W. Manley et al. · Structure · 2005 · 341 citations · Full text

Crystal Structure, Biochemistry, C-src Activation +8